Viamet Pharmaceuticals Announces Presentations at ID Week 2016 on Novel Antifungal Compounds VT-1161 and VT-1129

Data Highlights Company’s Robust Antifungal Pipeline

Viamet Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, today announced that data from preclinical studies of the novel antifungal compounds VT-1161 and VT-1129 will be presented on Friday, October 28^th at ID Week 2016, in New Orleans, Louisiana. VT-1161 and VT-1129 are orally-administered inhibitors of fungal CYP51. VT-1161 is currently in Phase 2 clinical development for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. VT-1129 is currently in Phase 1 clinical development for the treatment of cryptococcal meningitis.